<DOC>
	<DOC>NCT02813967</DOC>
	<brief_summary>This was a randomised, multicenter, phase 3 trial. Patients who were age of 70 years or older with histologically confirmed esophageal cancer were randomly assigned to S-1 concurrent with radiotherapy or radiotherapy alone.The primary endpoint was overall survival.</brief_summary>
	<brief_title>S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Histological or cytologic diagnosis of esophageal carcinoma ECOG performance status 01 Age:7085 years Joined the study voluntarily and signed informed consent form Patients must not have received any prior anticancer therapy Stage ⅠⅣB（AJCC 2009） Target lesions can be measured according to RECIST criteria No serious system dysfunction and immunodeficiency, Adequate organ function including the following: Hemoglobin ≥9 g/dL, WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L, platelet count ≥100x 109/L, TBIL&lt;1.5 x ULN, ALT and AST ≦ 2.5 x ULN, creatinine ≦ 1.5 x ULN Multiple carcinomas of the esophagus, Biopsyproven invasion of the tracheobronchial tree or tracheoesophageal fistula, Metastatic disease (M1b), A primary tumor that extended to within 2 cm of the gastroesophageal junction, Prior chemotherapy, prior thoracic radiation, surgical resection of the primary tumor, history of a second malignancy other than nonmelanoma skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>